Tata Nageswara Rao, Nils Hansen, Jan Stetka, Damien Luque Paz, Milena Kalmer,  Julian Hilfiker, Max Endele, Nouraiz Ahmed, Lucia Kubovcakova, Margareta Rybarikova, Hui Hao-Shen, Florian Geier, Christian Beisel, Stefan Dirnhofer, Timm Schroeder, Tim H. Brümmendorf, Dominik Wolf, Steffen Koschmieder and Radek C. Skoda. JAK2-V617F and interferon-a induce megakaryocyte-biased stem cells characterized by decreased long-term functionality. (2021) Blood, 137: 2139-51.

Nienhold R, Ashcroft P, Zmajkovic J, Rai S, Rao NR, Drexler B, Meyer SC, Lundberg P, Passweg JR, Leković D, Čokić VP, Bon-hoeffer S, Skoda RC. MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages. (2020) Blood, 136: 2591–95.

Rao TN, Hansen N, Hilfiker J, Rai S, Majewska JM, Leković D, Gezer D, Andina N, Galli S, Cassel T, Geier F, Delezie J, Nienhold R, Hao-Shen H, Beisel C, Di Palma S, Dime-loe S, Trebicka J, Wolf D, Gassmann M, Fan TWM, Lane AN, Handschin C, Dirn-hofer S, Kröger N, Hess C, Radimerski T, Koschmieder S, Čokić VP, Skoda RC. JAK2 mutant hematopoietic cells display metabolic alterations that can be target-ed to treat myeloproliferative neoplasms. (2019) Blood 134:1832–1846.

Drexler B, Passweg JR, Tzankov A, Bigler M, Theochari-des APA, Cantoni N, Keller P, Stussi G, Ruefer A, Benz R, Favre G, Lundberg P, Nienhold R, Fuhrer A, Biaggi  A, Manz MG, Bargetzi M, Mendez-Ferrer  S and Skoda RC, on behalf of the Swiss Group for Clinical Cancer Research (SAKK).  The sympathomimetic agonist mirabe-gron did not lower JAK2-V617F allele bur-den, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase 2 study SAKK 33/14. (2019) Haematologica, 104: 710–716.

Zmajkovic J, Lundberg P, Nienhold R, Lyngaas Torgersen M, Sundan A, Waage A Skoda RC. A gain-of-function mutation in EPO in familial erythrocytosis. (2018) N. Engl. J. Med., 378:924–930.